Matrix Metalloproteinase 3 and 9 As Genetic Biomarkers for the Occurrence of Cardiovascular Complications in Coronary Artery Disease: a Prospective Cohort Study

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Aug 12

PMID 35960412

Authors

Imen Guizani

Wiem Zidi

Yosra Zayani

Fourti Nesrine

Hayet Douik

Haifa Sanhaji

Mohamed Sami Mourali

Moncef Feki

Monia Allal-Elasmi

Affiliations

Soon will be listed here.

Abstract

Background: Matrix metalloproteinases (MMPs) are widely expressed in atherosclerosis lesions. The disequilibrium of MMPs driving to an overexpression or a lack of its level can be influenced by genetic variations. MMP-3 and MMP-9 may be affected by specific polymorphisms like - 1612 5 A/6A and the - 1562 C/T respectively. We aim in the present study to investigate prospectively the association between the - 1612 5 A/6A MMP-3 and - 1562 C/T MMP-9 polymorphisms and clinical outcomes in patients with coronary artery disease (CAD). This study is elaborated to reveal whether one of these polymorphisms is a probable predictor of cardiovascular complications in this CAD cohort.

Methods And Results: A total of 168 patients with CAD were prospectively followed up over a period of 5 years. Genotypes for the MMP-3 (-1612 5 A/6A) and MMP-9 (-1562 C/T) polymorphisms were performed using PCR-RFLP. Their levels were measured by ELISA in Sandwich test during the follow-up period, 39 cardiovascular outcomes occurred with 21 repeat targets for revascularization, 3 patients with Myocardial infarction, 8 for heart failure, 5 for Stroke and 2 for cardiovascular mortality. The MMP-3 5 A/6A polymorphism was related to the disease on the contrary of the MMP-9 -1562 C/T. Patients carrying the 5 A allele had a higher level of MMP-3 level and those who carried the 6 A allele had lower level (p = 0.04). After applied multivariable Cox-hazard models we revealed that the 6 A allele is independently associated to the disease complication. Kaplan-Meier survival test revealed that individuals having the 6 A allele had a lower survival rate than those with the 5 A allele (p = 0.04).

Conclusion: Our study suggests the disruption of the MMP-3 level may be due to the existence of the polymorphism - 1612 residing in its promoter region. MMP-3 can be considered as a marker of diagnosis and prediction in cardiovascular events.

Citing Articles

Matrix metalloproteinase-3 joins a growing list of proteases that regulate vascular calcification.

Giachelli C, Donato M, Scatena M Cardiovasc Res. 2024; 120(6):565-566.

PMID: 38630897 PMC: 11074787. DOI: 10.1093/cvr/cvae064.

A Set of Possible Markers for Monitoring Heart Failure and Cognitive Impairment Associated: A Review of Literature from the Past 5 Years.

Pagano M, Corallo F, DAleo P, Duca A, Bramanti P, Bramanti A Biomolecules. 2024; 14(2).

PMID: 38397422 PMC: 10886491. DOI: 10.3390/biom14020185.

IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification.

Li S, Shen S, Xu H, Cai S, Yuan X, Wang C Cell Death Discov. 2023; 9(1):164.

PMID: 37188676 PMC: 10185520. DOI: 10.1038/s41420-023-01457-3.

References

Henney A, Wakeley P, Davies M, Foster K, Hembry R, Murphy G . Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991; 88(18):8154-8. PMC: 52465. DOI: 10.1073/pnas.88.18.8154. View

Jefferis B, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L . Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2009; 208(2):557-63. PMC: 2822955. DOI: 10.1016/j.atherosclerosis.2009.08.018. View

Galis Z, Johnson C, Godin D, Magid R, Shipley J, Senior R . Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002; 91(9):852-9. DOI: 10.1161/01.res.0000041036.86977.14. View

Wagsater D, Zhu C, Bjorkegren J, Skogsberg J, Eriksson P . MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med. 2011; 28(2):247-53. DOI: 10.3892/ijmm.2011.693. View

Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y . Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003; 42(8):1429-37. DOI: 10.1016/s0735-1097(03)01062-3. View

Ye S . Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2005; 69(3):636-45. DOI: 10.1016/j.cardiores.2005.07.015. View

Zhang B, Ye S, Herrmann S, Eriksson P, de Maat M, Evans A . Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999; 99(14):1788-94. DOI: 10.1161/01.cir.99.14.1788. View

Guizani I, Zidi W, Zayani Y, Boudiche S, Hadj-Taieb S, Sanhaji H . Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study. Mol Biol Rep. 2019; 46(5):4699-4707. DOI: 10.1007/s11033-019-04914-4. View

Haberbosch W, Gardemann A . Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest. 2005; 65(6):513-22. DOI: 10.1080/00365510500206575. View

10.

Cho H, Chae I, Park K, Oh S, Lee M, Park Y . Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet. 2002; 47(2):88-91. DOI: 10.1007/s100380200006. View

11.

Kim J, Park H, Kwon J, Im E, Choi D, Jang Y . The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J. 2002; 43(4):473-81. DOI: 10.3349/ymj.2002.43.4.473. View

12.

Zhi H, Wang H, Ren L, Shi Z, Peng H, Cui L . Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep. 2009; 37(1):13-20. DOI: 10.1007/s11033-009-9482-x. View

13.

Opstad T, Pettersen A, Weiss T, Akra S, Ovstebo R, Arnesen H . Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta. 2011; 413(1-2):113-20. DOI: 10.1016/j.cca.2011.09.004. View

14.

Morgan A, Zhang B, Tapper W, Collins A, Ye S . Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl). 2003; 81(5):321-6. DOI: 10.1007/s00109-003-0441-z. View

15.

Abilleira S, Bevan S, Markus H . The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet. 2006; 43(12):897-901. PMC: 2563195. DOI: 10.1136/jmg.2006.040808. View

16.

Beilby J, Chapman C, Palmer L, McQuillan B, Thompson P, Hung J . Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population. J Hypertens. 2005; 23(3):537-42. DOI: 10.1097/01.hjh.0000160209.48479.ae. View

17.

Davies M . Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996; 94(8):2013-20. DOI: 10.1161/01.cir.94.8.2013. View

18.

Ye S, Whatling C, Watkins H, Henney A . Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett. 1999; 450(3):268-72. DOI: 10.1016/s0014-5793(99)00509-8. View

19.

Beyzade S, Zhang S, Wong Y, Day I, Eriksson P, Ye S . Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol. 2003; 41(12):2130-7. DOI: 10.1016/s0735-1097(03)00482-0. View

20.

Schwarz A, Haberbosch W, Tillmanns H, Gardemann A . The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers. 2003; 18(3):121-8. PMC: 3851962. DOI: 10.1155/2002/418383. View